Chemistry: molecular biology and microbiology – Enzyme – proenzyme; compositions thereof; process for...
Reexamination Certificate
2006-08-01
2006-08-01
Carlson, Karen Cochrane (Department: 1653)
Chemistry: molecular biology and microbiology
Enzyme , proenzyme; compositions thereof; process for...
Reexamination Certificate
active
07083957
ABSTRACT:
The present invention concerns methods of reducing the antigenicity of a proteinaceous compound while maintaining the compounds biological activity, as well as proteinaceous compositions with biological activity but reduced antigenicity. These methods and compositions have significant benefits to a subject in need of such compounds and compositions. Also included are modified toxin compounds that are truncated and/or possess reduce antigenicity. Such designer toxins have therapeutic, diagnostic, and preventative benefits, particularly as immunotoxins. Methods of treating cancer using these immunotoxins are provided.
REFERENCES:
patent: 4263279 (1981-04-01), Sela et al.
patent: 4414148 (1983-11-01), Jansen et al.
patent: 4522918 (1985-06-01), Schlom et al.
patent: 4590071 (1986-05-01), Scannon et al.
patent: 4650674 (1987-03-01), Aggarwal et al.
patent: 4671958 (1987-06-01), Rodwell et al.
patent: 4677064 (1987-06-01), Mark et al.
patent: 4753894 (1988-06-01), Frankel et al.
patent: 4771128 (1988-09-01), Ferris et al.
patent: 4801578 (1989-01-01), Monsigny et al.
patent: 4831122 (1989-05-01), Buchsbaum et al.
patent: 4863726 (1989-09-01), Stevens et al.
patent: 4870163 (1989-09-01), Rubin et al.
patent: 4888415 (1989-12-01), Lambert et al.
patent: 4894225 (1990-01-01), Zimmerman
patent: 4894227 (1990-01-01), Stevens et al.
patent: 4894443 (1990-01-01), Greenfield et al.
patent: 4935233 (1990-06-01), Bell et al.
patent: 4946778 (1990-08-01), Landner et al.
patent: 4962188 (1990-10-01), Frankel
patent: 4963354 (1990-10-01), Shepard et al.
patent: 4980457 (1990-12-01), Jansen et al.
patent: 5017371 (1991-05-01), Cummins
patent: 5019368 (1991-05-01), Epstein et al.
patent: 5032521 (1991-07-01), White et al.
patent: 5134075 (1992-07-01), Hellstrom et al.
patent: 5359046 (1994-10-01), Capon et al.
patent: 5621083 (1997-04-01), Better
patent: 5624827 (1997-04-01), Rosenblum et al.
patent: 5631348 (1997-05-01), Rosenblum et al.
patent: 5720954 (1998-02-01), Hudziak et al.
patent: 5744580 (1998-04-01), Better et al.
patent: 5770195 (1998-06-01), Hudziak et al.
patent: 5837491 (1998-11-01), Better et al.
patent: 6084073 (2000-07-01), Piatak, Jr.
patent: 6099842 (2000-08-01), Pastan et al.
patent: 6214974 (2001-04-01), Rosenblum et al.
patent: 6306626 (2001-10-01), Rosenblum et al.
patent: RE37462 (2001-12-01), Rosenblum et al.
patent: 6599505 (2003-07-01), Rosenblum
patent: 6669938 (2003-12-01), Rosenblum et al.
patent: 6750329 (2004-06-01), Rosenblum et al.
patent: 2003/0073163 (2003-04-01), Fernandez et al.
patent: 2003/0086919 (2003-05-01), Rosenblum et al.
patent: 2003/0134302 (2003-07-01), Fernandez et al.
patent: 2003/0186384 (2003-10-01), Barth et al.
patent: 2004/0009477 (2004-01-01), Fernandez et al.
patent: 2004/0013691 (2004-01-01), Rosenblum
patent: B79527/87 (1988-04-01), None
patent: B82047/87 (1988-06-01), None
patent: A13017/88 (1988-09-01), None
patent: A21725/88 (1989-03-01), None
patent: A30753/89 (1989-08-01), None
patent: 0118365 (1984-03-01), None
patent: 0160446 (1985-04-01), None
patent: 0150126 (1985-07-01), None
patent: 0184369 (1985-11-01), None
patent: 0226418 (1986-12-01), None
patent: 0222360 (1987-05-01), None
patent: 0256714 (1988-02-01), None
patent: 0281070 (1988-09-01), None
patent: 0305967 (1989-03-01), None
patent: 0336631 (1989-10-01), None
patent: 0350230 (1990-01-01), None
patent: 0396387 (1990-11-01), None
patent: 1564666 (1978-01-01), None
patent: 2148299 (1985-05-01), None
patent: 86121 (1981-07-01), None
patent: 62209098 (1986-12-01), None
patent: 190200 (1987-08-01), None
patent: WO 85/00974 (1984-08-01), None
patent: WO 86/05098 (1985-07-01), None
patent: WO 86/02945 (1986-05-01), None
patent: WO 87/00056 (1986-06-01), None
patent: WO 88/09343 (1988-12-01), None
patent: WO 88/09344 (1988-12-01), None
patent: WO 89/06692 (1989-07-01), None
patent: WO 90/00405 (1990-01-01), None
patent: WO 91/16071 (1991-10-01), None
patent: WO 94/26910 (1994-11-01), None
patent: WO 97/22364 (1997-06-01), None
patent: WO 97/46259 (1997-12-01), None
patent: WO 99/40198 (1999-08-01), None
patent: WO 99/45128 (1999-09-01), None
patent: WO 99/49059 (1999-09-01), None
patent: WO 99/51620 (1999-10-01), None
patent: WO 99/51766 (1999-10-01), None
patent: WO 00/34317 (2000-06-01), None
patent: WO 03/002598 (2003-01-01), None
Better et al. 1994; J. Biological Chemistry 269(13): 9644-9650.
Johnson et al. 1997; FEMS Microbiology Letters 146:91-96.
Parakh et al. 1995; Proceedings of the American Association for Cancer Research Annual Meeting 36:488, abstract # 2909.
Suhrbier et al. 1991; J. Immunology 147(8): 2507-2513.
U.S. Appl. No. 10/676,725, filed Oct. 1, 2003, Rosenblum.
U.S. Appl. No. 10/926,731, filed Aug. 26, 2004, Rosenblum.
Gase et al., “Functional significance of NH2- and COOH- terminal regions of staphylokinase in plasminogen activation,”Thrombosis and Haemostasis, 76(5):755-760, 1996.
Giacomini et al., “Modulation by recombinant DNA leukocyte (alpha) and fibroblast (beta) interferons of the expression and shedding of HLA- and tumor-associated antigens by human melanoma cells,”J. Immunol., 133(3):1649-1655, 1984.
Gillies et al., “Antigen binding and biological activities of engineered mutant chimeric antibodies with human tumor specificities,”Hum. Antibodies Hybridomas., 1:47-54, 1990.
Gould et al., “Phase I study of an anti-breast cancer immunotoxin by continuous infusion: report of a targeted toxic effect not predicted by animal studies,”J. Natl. Cancer Inst., 81:775-781, 1989.
Green et al., “Monoclonal antibody therapy for solid tumors,”Cancer Treat Rev., 26:269-286, 2000.
Greiner et al., “Differential effects of recombinant human leukocyte interferons on cell surface antigen expression,”Cancer Res., 46:4984-4990, 1986.
Greiner et al., “Enhanced expression of surface tumor-associated antigens on human breast and colon tumor cells after recombinant human leukocyte alpha-interferon treatment,”Cancer Res., 44:3208-3214, 1984.
Haddad et al., “Structural organization of the hCTLA-1 gene encoding human granzyme B,”Gene, 87(2):265-271, 1990.
Hamburger and Salmon, “Primary bioassay of human tumor stem cells,”Science, 197:461-463, 1977.
Hann et al., “Building ‘validated’ mouse models of human cancer,”Curr. Opin. Cell Biol., 13:778-784, 2001.
Hanson et al., “A cluster of hematopoietic serine protease genes is found on the same chromosomal band as the human α/δ T-cell receptor locus,”Proc. Natl. Acad. Sci., USA, 87:960-963, 1990.
Harlow et al.,Antibodies: A laboratory Manuel, Cold Spring Harbor Press, pp. 72-77, 92-97, 128-135, and 141-157, 1988.
Harper et al., “Proximity of the CTLA-1 serine esterase and Tcr alpha loci in mouse and man,”Immunogenetics, 28(6):439-444, 1988.
Henkart, “Mechanism of Lymphocyte-mediated Cytotoxicity,”Ann. Rev. Immunol., 3:31-58, 1985.
Hertler et al., “A phase I study of T101-ricin A chain immunotoxin in refractory chronic lymphocytic leukemia,”J. Biol. Response Mod., 7:97-113, 1987.
Hoogenboom et al., “Targeting of tumor necrosis factor to tumor cells: secretion by myeloma cells of a genetically engineered antibody-tumor necrosis factor hybrid molecule,”Biochim Biophys Acta., 1096:345-354, 1991.
Huston et al., “Single-chain immunotechnology of Fv analogues and fusion proteins,” inImmunotechnology, Gosling and Reen (eds), p. 47-60, 1993.
Imai et al, “[Current status of monoclonal antibodies to human melanoma and its application],”Gan To Kagaku Ryoho., 10:852-860, 1983 (abstract in English).
Imai et al., “Differential effect of interferon on the expression of tumor-associated antigens and histocompatibility antigens on human melanoma cells: relationship to susceptibility to immune lysis mediated by monoclonal antibodies,”J. Immunol., 127(2):505-509, 1981.
Johnson, “Review: Noncaspase proteases in apoptosis,”Leukemia, 14:1695-1703, 2000.
Juhl et al., &#x
Cheung Lawrence
Rosenblum Michael G.
Carlson Karen Cochrane
Fulbright & Jaworski L.L.P.
Reasearch Development Foundation
LandOfFree
Modified proteins, designer toxins, and methods of making... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Modified proteins, designer toxins, and methods of making..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Modified proteins, designer toxins, and methods of making... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3616436